story of the week
Trastuzumab Deruxtecan in Patients With CNS Involvement From HER2+ Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Neuro-Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trastuzumab Deruxtecan in Patients with Central Nervous System Involvement from HER2-Positive Breast Cancer: The DEBBRAH Trial
Neuro-oncology 2022 May 26;[EPub Ahead of Print], JM Pérez-García, MV Batista, P Cortez, M Ruiz-Borrego, JM Cejalvo, J de la Haba-Rodriguez, L Garrigós, F Racca, S Servitja, S Blanch, M Gion, M Nave, M Fernández-Abad, A Martinez-Bueno, A Llombart-Cussac, M Sampayo-Cordero, A Malfettone, J Cortés, S BragaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.